Rapamycin has a unique stature of being a miracle drug with numerous applications including many are yet to be verified. When it was isolated for the first time in 1972, researchers did not think the possibility of the drugs in vat areas and used just as an anti-fungal compound. The researches in the later years proved that it could cure many health conditions of the human body. Among the researchers, Mikhail Blagosklonny has dedicated his time and efforts in Rapamycin significantly and identified many applications of the drug in the modern medical science. For people who do not know the extensive range of applications of the drug, Blagosklonny explained some of the best uses of it in the medical world. Read more about Mikhail on Crunchbase.
He says that the drug exhibits excellent immunosuppressant properties which makes it an ideal choice for suppressing the body rejection tendency when transplanting new organs into it. While other drugs with similar characteristics bear a higher level of toxicity in kidneys, Rapamycin showcases the least. It is also the best option for treating the hemolytic-uremic condition which is a mix of kidney failure, meager platelet count, and anemia. When going for a kidney transplant, the new organ found to be prone to the disease and, Rapamycin has the power to limit such probabilities.
The researchers of Blagosklonny showed that the drug could even be useful in treating cancer condition due to its antiproliferative properties. The drug found to be increasing the immunity of the human body especially against cancer cells – playing a major role in restricting the disease as well as improving recovery. When taken in right doses, Rapamycin creates a regression against cancer cells in the human body. It is also the primary choice of drug in TSC and facial angiofibromas as well. The most important application of Rapamycin is it improves the quality lifespan of humans if taken in right doses. Mikhail Blagosklonny did extensive research in the area, and the tests on mice produced excellent results as well. He has also set his plans to make his tests and trials extended to other organisms to arrive more accurate conclusions. Read more on Impact Journals.
Blagosklonny is also credited with philanthropic and academic contributions as well. He has expressed his vision that every individual across the world gets the best treatment options without considering the financial status. While he conducts researches in aging and cancer, the focus of Blagosklonny is to produce results based on effectiveness and affordability. He has done vast research on the relationship between cancer and the age – people who are above a certain age found to be more vulnerable to the disease.
While coming to cancer research and treatment development, Blagosklonny wanted solutions that can specifically target the diseased cells without making any trouble to the healthy cells. It is already proved that such a precision medication option is vital in the overall recovery of the patient. While conducting researches, Blagosklonny does not think that he would make a breakthrough in cancer or anti-aging. Instead, he wants to ensure that he is encouraging his colleagues and junior researchers to continue from where he stops.
There are numerous articles you can read about Oncotarget today, and most of them would not be able to tell you everything about it. In this article, we will conflate most of the pieces that you need to make sure that you can learn about what’s the latest thing about Oncotarget without wasting your time. Sure, most of what you read online is ethereal and will disappear after one reading. We will try to address that in this article. Shall we go on?
The Oncotarget Recap
One of the many articles you need to read from Oncotarget is the one about Genetic Polymorphisms in HLA-DP and its relationship with STAT4 nephropathy. In one of the most stellar research articles in ResearchGate, it is shown that Oncotarget was able to be the publishing journal who spread the information about the pathogenesis of IgA Nephropathy. In the ResearchGate article, it was shown that IgA nephropathy or (IgAN) can be initiated by what is now known as the Glomerular Deposition of Polymeric IgA1. Check Oncotarget at scimagojr.com
You can also see from the abstract of this article the information from Oncotarget that states how the new development in genetics and pathogenesis is able to find new ways to address the issues of diseases. It is also shown in the article that the local pathogens in one’s body could be related to the multilocus adaptation of the cells in one’s body.
It is also an added information from Oncotarget the statement that the perspective of the existing treatment options today in addressing kidney disease concerns should be able to find new affordable means. That should be the goal of medicine. This, fortunately, is what is driving Oncotarget to publish more journals. Watch this video on Youtube.
The EurekaAlert Article
Another interesting and relevant info you should learn, too, about Oncotarget is that it is one of the publishing firms that have found alternative therapies to thyroid cancer and other diseases. With EurekaAlert’s feature about Oncotarget’s research, it is now evident that Oncotarget is getting more relevant in its pursuit to fix all the necessary problems ingrained in the medical issues of curing thyroid cancer.
Curiosity can get a person in trouble or it can help them to do big things and live a successful life. When Glen Wakeman was given the chance to talk about something that has helped him to reach the successful place that he is at, he shared that he is someone who is very curious. This man follows after his curiosity and he allows it to help him come up with new ideas and new ways of doing things. The curiosity that Glen Wakeman has helps him to push on even when times are tough and he is deep in a project that is taking a lot out of him. Read more about his interview at Ideamensch.
Some people have only worked jobs that they love as they have moved through life, and there are others who have worked jobs that they hated. Glen Wakeman is someone who has come through a job that he really did not like. This man shared about a job that he had where he was given the task of cleaning bathrooms. This job was not exciting and it was not fun. Glen Wakeman shared that he learned to never take anything for granted while he was working this humbling job. View Glen Wakeman’s profile linkedin.com.
Glen Wakeman is a well-educated individual. He has a degree from the University of Chicago, and he also studied at the University of Scranton. He is someone who has much work experience, having spent over twenty years working for GE Capital. Glen Wakeman is someone who is a financial services executive and who takes on that job in a smart way. He is someone who is a board member and who has much to offer as he handles that responsibility. Glen Wakeman is someone who others look up to, and he is someone who has much to offer to those who are looking to learn from him.